Latanox

Latanoprost, the active ingredient in Latanox, is a prostaglandin analog presented as a topical ophthalmic solution for ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used to manage ocular conditions characterized by elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent development of glaucoma.

Latanoprost may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye redness or hyperemia - Eye irritation or foreign‑body sensation - Increased eyelash growth (hypertrichosis) - Darkening of the iris (especially in patients with mixed‑color eyes) - Blurred vision shortly after instillation - Mild eye discomfort or itching

Serious or Rare Side Effects: - Uveitis or intra‑ocular inflammation - Macular edema leading to visual disturbance - Allergic reactions such as swelling or rash around the eye - Sudden loss of vision or severe visual changes - Persistent ocular pain or photophobia - Unusual changes in corneal health

Before using Latanox, consider the following precautions.

Avoid use in patients with active ocular infection: risk of worsening infection. Do not use if hypersensitivity to latanoprost or any excipient: may cause severe irritation. Monitor intra‑ocular pressure after initiation: adjust therapy based on response. Use caution in patients with a history of uveitis or macular edema: may exacerbate condition. Avoid contact lens wear immediately after instillation: solution can affect lens material. Store below 25°C: keep in the original bottle, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Combined use with other ocular hypotensive agents (e.g., beta‑blockers) may cause excessive pressure lowering. - Concurrent systemic carbonic anhydrase inhibitors can add to intra‑ocular pressure reduction. - Use with non‑steroidal anti‑inflammatory eye drops may increase ocular irritation.

Moderate Interactions (Monitor Closely): - Concomitant ocular steroids may reduce steroid efficacy. - Systemic antihistamines may cause dry eye, worsening discomfort. - Use with other prostaglandin analogs offers no additive benefit and raises side‑effect risk.